Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
about
Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionFine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.A Multi-Vector, Multi-Envelope HIV-1 VaccineInsensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype BA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinRapid evolution of the neutralizing antibody response to HIV type 1 infectionThe rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategiesProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.Immunoprophylaxis against mother-to-child transmission of HIV-1Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusingDistribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection.Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV InfectionProfiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1.Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infantImmune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systemsRole of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12.Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaquesSequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesAntibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heteroloRhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV/AIDSLack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodiesPotent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.Antibodies for prevention of mother-to-child transmission of HIV-1Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particlesThe roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
P2860
Q27472672-4EAF5019-DD40-4BEA-A614-094985B66ACCQ27676864-F71725C7-FCF9-4738-B9C2-2221F960BDB7Q28217208-620734E4-BB76-411F-95F4-5BD53BB2E434Q28389250-6DEBA4A8-780F-4FF2-841F-D4E509A932F6Q28469023-DB997554-B079-4B28-BBBD-BF4AE1AA917CQ28743092-5FC836CB-C023-43E9-8C10-C34B40C1AF05Q29618603-1AB358CE-FF41-403E-95C2-579748477A3FQ30374404-185F10FF-FB22-4684-BC40-7A67C4FE1CBAQ30379200-1405E5A7-2848-4785-846A-3F666D1211CBQ30425594-4CB3A84F-E3CB-4DEB-97CF-F1322CE9EB68Q33250208-2A4F772C-D427-4CC1-BD55-849AE56782D8Q33392865-E5DFF6AC-DEFF-4466-A735-FA96CE606CB6Q33554940-7CD78BCF-5824-450D-B347-92AB64601C9AQ33571825-C51B6826-B35A-424A-B2E6-C1E590D134FEQ33620546-693968CC-9BED-4E0C-80D1-6C2090BDDCC1Q33749827-48BCDEBD-2F39-476D-A921-250BDE0FA50AQ33781055-260AB95D-E7B0-4999-ABC2-32B9FDBC796FQ33930424-04F48294-8F20-4546-876B-DB5901BC9329Q33955745-4EAF3BF0-9C67-4F53-9341-93C553046584Q34301874-1A355638-FD38-4E68-B1C1-2500E11FC73BQ34389901-C4791204-C816-4CB7-9318-C13C8F5E91FEQ34637663-4EB6AA4F-0A95-4024-8F26-83A01FA5FCE4Q34717113-85A6A721-EC71-4930-9F98-B59294F3A944Q34781840-048454A4-3D7E-4F30-BA55-1BE38358D7C1Q34962907-F8CC0E65-7536-406B-82CD-12E3473A04EDQ34982715-5215498F-E785-47FA-A89F-38E7581ADA30Q35024202-1A8F67B0-D350-4D50-9C50-C09E56910E6DQ35024276-038C3EE8-2E85-4DCC-977A-3D0B25CC3F37Q35097510-EF53080D-1360-4D6E-A512-3A3D67CAEDD4Q35167400-6402624F-FDE1-4F7C-8DDA-7FC289185301Q35182076-13B4280A-131C-4F95-8205-22E458D06242Q35540731-CD3186B3-3FA7-4BEF-B3C2-51F416CB4FC5Q35591075-0D38809E-E944-4569-8732-C378392EEF15Q35603504-7B39C6F9-CDCE-4AB3-91A0-77F6DC029C05Q35619402-360A0CE6-BC41-4276-BFF4-5A020AD12BABQ35704086-7A908426-10E8-4B0A-A5AE-A2B4925BC776Q35851774-5B4748BA-A2D4-4030-A7E7-EBFDE46A4366Q35851778-6A54B219-EA37-4DBC-AE58-8F0AE3CFA9F4Q35857221-6E721FA8-584B-4ABE-A726-686938AFC548Q36099376-83296C64-B586-48DF-B3A1-23E8B6A3C138
P2860
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Postnatal passive immunization ...... unodeficiency virus challenge.
@ast
Postnatal passive immunization ...... unodeficiency virus challenge.
@en
type
label
Postnatal passive immunization ...... unodeficiency virus challenge.
@ast
Postnatal passive immunization ...... unodeficiency virus challenge.
@en
prefLabel
Postnatal passive immunization ...... unodeficiency virus challenge.
@ast
Postnatal passive immunization ...... unodeficiency virus challenge.
@en
P2093
P2860
P1433
P1476
Postnatal passive immunization ...... unodeficiency virus challenge.
@en
P2093
B J Bernacky
D C Anderson
D C Montefiori
F Ferrantelli
G Stiegler
H Katinger
H M McClure
J Andersen
P2860
P304
P356
10.1128/JVI.75.16.7470-7480.2001
P577
2001-08-01T00:00:00Z